https://ppubs.uspto.gov/pubwebapp/
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $50 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $50 price target.
Related Posts
Biden Administration Commits $15.5B To Upgrade Automaker Factories For EV Production
In the newest push towards electric vehicles, the U.S. Department of Energy on Thursday announced a funding package…
Tesla, Amazon, Provention Bio, Polestar, Palo Alto Networks: Musk’s Court Case, Job Cuts, Earnings Pull Investor Eyeballs
Major Wall Street indices closed in the red and bond yields rose on Thursday as investors and traders digested comments from a Federal Reserve official in the context of potential interest rate hikes in the future. St.
Citigroup Upgrades Charles Schwab to Buy, Lowers Price Target to $75
Citigroup analyst Chris Allen upgrades Charles Schwab (NYSE:SCHW) from Neutral to Buy and lowers the price target from $83 to $75.